Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

However, interventional studies to test this effect are lacking.

Who Took Part

PubMed indexes the participants as middle-aged adults, women only.

The subjects were 1179 community-dwelling women randomly selected from the population of healthy postmenopausal women aged >55 y in a 9-county rural area of Nebraska centered at latitude 41.4 degrees N.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

This was a 4-y, population-based, double-blind, randomized placebo-controlled trial.

The primary outcome was fracture incidence, and the principal secondary outcome was cancer incidence.

What Was Measured

PubMed files the paper under topics including Calcifediol, Calcium, Dietary Supplements, Fractures, Bone, Incidence, Kaplan-Meier Estimate and Logistic Models.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2007 (The American journal of clinical nutrition), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.